ArticleThyroid : official journal of the American Thyroid Association2019
Complete Surgical Resection Following Neoadjuvant Dabrafenib Plus Trametinib in
Open access · hybridAbstract read
In one paragraph
Article in Thyroid : official journal of the American Thyroid Association, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 120 papers, 3 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
120citing papers in PubMed, 3 pooled it
19.0field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
120 citing papers in PubMed, 3 syntheses or guidelines pooled it, 226 citations in OpenAlex.
- The 2024 revised clinical guidelines on the management of thyroid tumors by the Japan Association of Endocrine Surgery.Endocrine journal · 2025Guideline
- Efficacy and safety of BRAF/MEK inhibitors in BRAFV600E-mutated anaplastic thyroid cancer: a systematic review and meta-analysis.Endocrine · 2024Pooled it
- 2021 American Thyroid Association Guidelines for Management of Patients with Anaplastic Thyroid Cancer.Thyroid : official journal of the American Thyroid Association · 2021Guideline
- Precision treatment guided by patient-derived organoids-based drug testing for locally advanced thyroid cancer: a single arm, phase 2 study.Endocrine · 2025Trial
- Radiotherapy and paclitaxel plus pazopanib or placebo in anaplastic thyroid cancer (NRG/RTOG 0912): a randomised, double-blind, placebo-controlled, multicentre, phase 2 trial.The Lancet. Oncology · 2023Trial
- Dabrafenib plus trametinib in patients with BRAF V600E-mutant anaplastic thyroid cancer: updated analysis from the phase II ROAR basket study.Annals of oncology : official journal of the European Society for Medical Oncology · 2022Trial
- Signaling pathways and targeted therapy in high‑risk refractory thyroid cancer: From bench to bedside (Review).International journal of oncology · 2026Review
- Neoadjuvant therapy in thyroid cancer: an emerging approach.Endocrine · 2026Review
- Latin American Thyroid Society expert panel consensus on anaplastic thyroid cancer.Archives of endocrinology and metabolism · 2026Article
- Neoadjuvant Therapies for Thyroid Cancer: A Scoping Review.The Laryngoscope · 2026Article
- Thyroid Cancer: Epidemiology, Diagnosis, and Treatment.Deutsches Arzteblatt international · 2026Review
- Neoadjuvant Combination Therapy with Tyrosine Kinase and Immune Checkpoint Inhibitors in Anaplastic Thyroid Cancer: A Single-Center, Real-World Experience.Annals of surgical oncology · 2026Article
- ASO Author Reflections: Neoadjuvant Combination Therapy with Tyrosine Kinase and Immune Checkpoint Inhibitors in Anaplastic Thyroid Cancer.Annals of surgical oncology · 2026Article
- Can Immunotherapy Improve Neoadjuvant Response and Allow Surgical Resection in Locally Advanced Anaplastic Thyroid Cancer?Annals of surgical oncology · 2026Article
- Recent Advances in Neoadjuvant Treatment of Anaplastic Thyroid Carcinoma: A Narrative Review.Current treatment options in oncology · 2026Review
- Role of the ETV5/p38 Signaling Axis in Aggressive Thyroid Cancer Cells.Molecular cancer therapeutics · 2026Article
- Fatal tracheal perforation following Dabrafenib-Trametinib therapy inJCEM case reports · 2026Article
- A synergistic drug combination that aids our battle against anaplastic thyroid carcinoma: a case report and discussion.Hormones (Athens, Greece) · 2026Article
- Implementing a Rapid Response Pathway for Anaplastic Thyroid Cancer in a Universal Healthcare System.Laryngoscope investigative otolaryngology · 2026Article
- New insights into the tumor immune microenvironment and immunotherapy of thyroid cancer.Frontiers in immunology · 2026Review
60 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
20 authors at 1 institution in 1 country.
Jennifer R Wang1Division of Surgery, Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Mark E Zafereo1Division of Surgery, Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Ramona Dadu2Division of Internal Medicine, Department of Endocrine Neoplasia & Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Renata Ferrarotto3Department of Thoracic/Head & Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Naifa L Busaidy2Division of Internal Medicine, Department of Endocrine Neoplasia & Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Charles Lu3Department of Thoracic/Head & Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Salmaan Ahmed4Department of Diagnostic Imaging, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Maria K Gule-Monroe4Department of Diagnostic Imaging, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Michelle D Williams5Department of Pathology, and The University of Texas MD Anderson Cancer Center, Houston, Texas.
Erich M Sturgis1Division of Surgery, Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Ryan P Goepfert1Division of Surgery, Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Neil D Gross1Division of Surgery, Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Stephen Y Lai1Division of Surgery, Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Gary Brandon Gunn6Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Jack Phan6Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
David I Rosenthal6Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Clifton David Fuller6Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
William H Morrison6Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Priyanka Iyer2Division of Internal Medicine, Department of Endocrine Neoplasia & Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Maria E Cabanillas2Division of Internal Medicine, Department of Endocrine Neoplasia & Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston, Texas.
The University of Texas MD Anderson Cancer Center · US
Funding
Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8MNCI NIH HHS P30 CA016672
Abstract
PubMed holds no abstract for this paper.
Indexed as
Neoadjuvant TherapyThyroidectomyAgedAntibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsChemoradiotherapy, AdjuvantDisease-Free SurvivalFemaleHumansImidazolesMaleMiddle AgedMutationNeck DissectionNeoplasm Recurrence, LocalNeoplasm StagingAntibodies, Monoclonal, HumanizedBRAF protein, humandabrafenibImidazolesOximespembrolizumabProto-Oncogene Proteins B-rafPyridonesPyrimidinonestrametinibanaplastic thyroid cancerchemotherapydabrafenibdedifferentiatedpembrolizumabsarcomatoidsquamoussurgerytargeted therapytrametinibundifferentiated
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.